Article Information
History
- November 12, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Jostein Starrfelt1,#,
- Eirik Alnes Buanes2,3,
- Lene Kristine Juvet4,5,
- Trude Marie Lyngstad1,
- Gunnar Øyvind Isaksson Rø5,
- Lamprini Veneti1 and
- Hinta Meijerink4
- 1Department of Infection Control and Preparedness, Norwegian Institute of Public Health, Oslo, Norway
- 2Norwegian Intensive Care and Pandemic Registry (NIPaR), Helse Bergen Health Trust, Bergen, Norway
- 3Department of Anaesthesiology and Intensive Care Haukeland University Hospital, Bergen, Norway
- 4Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway
- 5Department of Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway
- ↵#Corresponding author: Jostein Starrfelt - jostein.starrfelt{at}fhi.no
Posted November 12, 2021.
Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, January – September 2021
